Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation

J Thorac Oncol. 2013 Nov;8(11):e96-8. doi: 10.1097/JTO.0b013e3182a008ed.

Authors

Gouji Toyokawa¹, Mitsuhiro Takenoyama, Sawori Watanabe, Ryo Toyozawa, Eiko Inamasu, Miyako Kojo, Yoshimasa Shiraishi, Yosuke Morodomi, Tomoyoshi Takenaka, Fumihiko Hirai, Masafumi Yamaguchi, Kenichi Taguchi, Takashi Seto, Yukito Ichinose

Affiliation

¹ *Department of Thoracic Oncology and †Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.

PMID: 24128725
DOI: 10.1097/JTO.0b013e3182a008ed

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma / pathology
Adult
Anaplastic Lymphoma Kinase
Crizotinib
Disseminated Intravascular Coagulation / drug therapy*
Disseminated Intravascular Coagulation / genetics
Disseminated Intravascular Coagulation / pathology
Female
Gene Rearrangement
Humans
In Situ Hybridization, Fluorescence
Liver Neoplasms / drug therapy*
Liver Neoplasms / genetics
Liver Neoplasms / secondary
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Receptor Protein-Tyrosine Kinases / genetics*

Substances

Protein Kinase Inhibitors
Pyrazoles
Pyridines
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases